EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Deubiquitinating enzyme USP28 inhibitor AZ1 alone and in combination with cisplatin for the treatment of non-small cell lung cancer

Yiqiong Song, Longhao Wang, Yuanyuan Zheng, Lanqi Jia, Chunwei Li, Ke Chao, Lifeng Li, Shilong Sun, Yujie Wei, Yahao Ge, Yaqi Yang, Lili Zhu und 2 weitere

Apoptosis · 2024-10 · 29 (9-10) · 1793-1809

DOI: 10.1007/s10495-024-02008-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Apoptosis, online erschienen am 02.09.2024. Verfasst von Yiqiong Song und 13 weiteren Autor:innen. Beteiligte Einrichtung: Internet Medical and System Applications of National Engineering Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Cisplatin, Ubiquitin Thiolesterase, Lung Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Collaborative Innovation Major Project of Zhengzhou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is one of the most common malignant tumors. Despite decades of research, the treatment of lung cancer remains challenging. Non-small cell lung cancer (NSCLC) is the primary type of lung cancer and is a significant focus of research in lung cancer treatment. The deubiquitinase ubiquitin-specific protease 28 (USP28) plays a role in the progression of various tumors and serves as a potential therapeutic target. This study aims to determine the role of USP28 in the progression of NSCLC. We examined the impact of the USP28 inhibitor AZ1 on the cell cycle, apoptosis, DNA damage response, and cellular immunogenicity in non-small cell lung cancer. We observed that AZ1 and siUSP28 induce DNA damage, leading to the activation of Noxa-mediated mitochondrial apoptosis. The dsDNA and mtDNA released from DNA damage and mitochondrial apoptosis activate tumor cell immunogenicity through the cGAS-STING signaling pathway. Simultaneously, targeting USP28 promotes the degradation of c-MYC, resulting in cell cycle arrest and inhibition of DNA repair. This further promotes DNA damage-induced cell apoptosis mediated by the Noxa protein, thereby enhancing tumor cell immunogenicity mediated by dsDNA and mtDNA. Moreover, we found that the combination of AZ1 and cisplatin (DDP) can enhance therapeutic efficacy, thereby providing a new strategy to overcome cisplatin resistance in NSCLC. These findings suggest that targeting USP28 and combining it with cisplatin are feasible strategies for treating NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCisplatinUbiquitin ThiolesteraseLung NeoplasmsApoptosisDNA DamageHumansCell Line, TumorAnimalsMiceSignal TransductionMitochondriaProto-Oncogene Proteins c-bcl-2Antineoplastic AgentsXenograft Model Antitumor AssaysMice, NudeAntineoplastic Combined Chemotherapy ProtocolsPiperidones

Stichwörter der Autor:innen

ApoptosisCell cycleDDRNoxaUSP28c-MYC

Substanzen

CisplatinUbiquitin ThiolesteraseUSP28 protein, humanProto-Oncogene Proteins c-bcl-23,5-bis((4-nitrophenyl)methylidene)-1-prop-2-enoylpiperidin-4-oneAntineoplastic AgentsPMAIP1 protein, humanPiperidones

Autor:innen und Institutionen

  • Internet Medical and System Applications of National Engineering Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
  • Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
  • Department of Oncology, Henan Provincial People's Hospital and Zhengzhou University People's Hospital, Zhengzhou, 450003, Henan, China.
  • Department of Pharmacy, The First Affiliated Hospital of Henan University of CM, Zhengzhou, 477150, Henan, China.
  • Internet Medical and System Applications of National Engineering Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. zhaojie@zzu.edu.cn.
  • Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. zhaojie@zzu.edu.cn.

Förderung

  • Collaborative Innovation Major Project of Zhengzhou

Zitieren

APA

Song, Y., Wang, L., Zheng, Y., Jia, L., Li, C., Chao, K., Li, L., Sun, S., Wei, Y., Ge, Y., Yang, Y., Zhu, L., Zhang, Y., & Zhao, J. (2024). Deubiquitinating enzyme USP28 inhibitor AZ1 alone and in combination with cisplatin for the treatment of non-small cell lung cancer. Apoptosis, 29(9-10), 1793-1809. https://doi.org/10.1007/s10495-024-02008-6

Vancouver

Song Y, Wang L, Zheng Y, Jia L, Li C, Chao K, et al. Deubiquitinating enzyme USP28 inhibitor AZ1 alone and in combination with cisplatin for the treatment of non-small cell lung cancer. Apoptosis. 2024;29(9-10):1793-1809. doi:10.1007/s10495-024-02008-6

BibTeX
@article{Song2024,
  author = {Song, Yiqiong and Wang, Longhao and Zheng, Yuanyuan and Jia, Lanqi and Li, Chunwei and Chao, Ke and Li, Lifeng and Sun, Shilong and Wei, Yujie and Ge, Yahao and Yang, Yaqi and Zhu, Lili and Zhang, Yixing and Zhao, Jie},
  title = {Deubiquitinating enzyme USP28 inhibitor AZ1 alone and in combination with cisplatin for the treatment of non-small cell lung cancer},
  journal = {Apoptosis},
  year = {2024},
  volume = {29},
  number = {9-10},
  pages = {1793--1809},
  doi = {10.1007/s10495-024-02008-6}
}
Kostenlos starten →